Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease

Gao JingJing; Wang Tao; Jiang YuanYe; Cao Qin

doi:10.3969/j.issn.1001-5256.2020.08.044

Volume 36 Issue 8

Aug. 2020

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2020 > 36(8): 1880-1882

PDF( 1840 KB)

Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2020.08.044

Department of Gastroenterology, Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Research funding:

Published Date: 2020-08-20

Abstract

Abstract

The incidence rate of nonalcoholic fatty liver disease(NAFLD) is increasing year by year and NAFLD has become one of the most common liver diseases in the world.Metabolomics follows the research thoughts of genomics and proteomics and conducts a quantitative analysis of all metabolites in organisms to explore the association between metabolites and physiological and pathological changes,which provides a new way for studying the traditional Chinese medicine diagnosis and treatment of NAFLD.This article summarizes the research advances in metabolomics and traditional Chinese medicine syndromes in NAFLD,so as to provide new thoughts and methods for further exploration of NAFLD.
- non-alcoholic fatty liver disease,
- metabolomics,
- symptom complex

FullText(HTML)

References(37)

References

[1] COBBINA E,AKHLAGHI F. Non-alcoholic fatty liver disease(NAFLD)-pathogenesis,classification,and effect on drug metabolizing enzymes and transporters[J]. Drug Metab Rev,2017,49(2):197-211.

[2] TU LN,SHOWALTER MR,CAJKA T,et al. Metabolomic characteristics of cholesterol-induced non-obese nonalcoholic fatty liver disease in mice[J]. Sci Rep,2017,7(1):6120.

[3] CHEN F,ESMAILI S,ROGERS GB,et al. Lean NAFLD:A distinct entity shaped by differential metabolic adaptation[J].Hepatology,2020,71(4):1213-1227.

[4] SANYAL AJ,FRIEDMAN SL,MCCULLOUGH AJ,et al. Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis:Findings and recommendations from an American Association for the Study of Liver Diseases-U. S. Food and Drug Administration Joint Workshop[J]. Hepatology,2015,61(4):1392-1405.

[5] YOUNOSSI ZM,KOENIG AB,ABDELATIF D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology,2016,64(1):73-84.

[6] LI J. Epidemiology characteristics of nonalcoholic fatty liver disease in Asia[J]. J Clin Hepatol,2018,34(12):34-38.(in Chinese)李婕．亚洲地区非酒精性脂肪性肝病的流行病学特点[J]．临床肝胆病杂志，2018,34(12):34-38.

[7] ZHANG AH,SUN H,QIU S,et al. Recent highlights of metabolomics in Chinese medicine syndrome research[J]. Evid Based Complement Alternat Med,2013,2013:402159.

[8] EVANGELATOS N,BAUER P,REUMANN M,et al. Metabolomics in sepsis and its impact on public health[J]. Public Health Genomics,2017,20(5):274-285.

[9] LANS I,GANTNER M,MURINELLO S,et al. Metabolomics in the study of retinal health and disease[J]. Prog Retin Eye Res,2019,69:57-79.

[10] CHEN X,YU D. Metabolomics study of oral cancers[J].Metabolomics,2019,15(2):22.

[11] HYTYLINEN T. Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications[J]. Expert Rev Mol Diagn,2012,12(5):527-538.

[12] NEMKOV T,REISZ JA,GEHRKE S,et al. High-throughput metabolomics:Isocratic and gradient mass spectrometrybased methods[J]. Methods Mol Biol,2019,1978:13-26.

[13] HE J. Study on mechanism of collagen-induced arthritis(CIA)rats treated with moxibustion based on urinary metabolomics[D].Nanjing:Nanjing University of Chinese Medicine,2019.(in Chinese)何静．基于尿液代谢组学艾灸治疗胶原诱导型关节炎大鼠的作用机制研究[D]．南京:南京中医药大学，2019.

[14] KHUSIAL RD,CIOFFI CE,CALTHARP SA,et al. Development of a plasma screening panel for pediatric nonalcoholic fatty liver disease using metabolomics[J]. Hepatol Commun,2019,3(10):1311-1321.

[15] LI J,ZHAO Y,HUANG C,et al. Serum metabolomic analysis of the effect of exercise on nonalcoholic fatty liver disease[J].Endocr Connect,2019,8(4):299-308.

[16] KALHAN SC,GUO L,EDMISON J,et al. Plasma metabolomic profile in nonalcoholic fatty liver disease[J]. Metabolism,2011,60(3):404-413.

[17] DONG S,ZHAN ZY,CAO HY,et al. Urinary metabolomics analysis identifies key biomarkers of different stages of nonalcoholic fatty liver disease[J]. World J Gastroenterol,2017,23(15):2771-2784.

[18] MICCHELI A,CAPUANI G,MARINI F,et al. Urinary(1)HNMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment[J]. Int J Obes(Lond),2015,39(7):1118-1125.

[19] VINAIXA M,RODRGUEZ MA,RULL A,et al. Metabolomic assessment of the effect of dietary cholesterol in the progressive development of fatty liver disease[J]. J Proteome Res,2010,9(5):2527-2538.

[20] LI ZH,ZHANG N,WANG Y,et al. Mechanism of Yinchenhao Decoction in treating non-alcoholic fatty liver based on 16S rRNA technique and metabonomics[J]. Chin J Tradit Chin Med Pharm,2019,34(5):1908-1913.(in Chinese)李自辉，张娜，王宇，等．基于16S rRNA技术与代谢组学探究茵陈蒿汤治疗非酒精性脂肪肝的作用机制[J]．中华中医药杂志，2019,34(5):1908-1913.

[21] FAN SC,GAO Y,ZHANG HZ,et al. Untargeted and targeted metabolomics and their applications in discovering drug targets[J]. Prog in Pharm Sci,2017,41(4):263-269.(in Chinese)范仕成，高悦，张慧贞，等．非靶向和靶向代谢组学在药物靶点发现中的应用[J]．药学进展，2017,41(4):263-269.

[22] JOHNSON CH,IVANISEVIC J,SIUZDAK G. Metabolomics:Beyond biomarkers and towards mechanisms[J]. Nat Rev Mol Cell Biol,2016,17(7):451-459.

[23] FELDMAN A,EDER SK,FELDER TK,et al. Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver:A targeted metabolomics approach[J]. Diabetes Metab,2019,45(2):132-139.

[24] PAPANDREOU C,BULLM,TINAHONES FJ,et al. Serum metabolites in non-alcoholic fatty-liver diease development or reversion; a targeted metabolomic approach within the PREDIMED trial[J]. Nutr Metab,2017,14:58.

[25] XU Y,HAN J,DONG J,et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development[J]. Int J Mol Sci,2019,20(5):1220.

[26] ZHU H,WANG Z,WU Y,et al. Untargeted metabonomics reveals intervention effects of chicory polysaccharide in a rat model of non-alcoholic fatty liver disease[J]. Int J Biol Macromol,2019,128:363-375.

[27] SETHI S,BRIETZKE E. Recent advances in lipidomics:Analytical and clinical perspectives[J]. Prostaglandins Other Lipid Mediat,2017,128-129:8-16.

[28] YANG RX,HU CX,MI YQ,et al. A serum lipidomic study of patients with non-alcoholic fatty liver disease[J]. Chin J Hepatol,2017,25(2):122-127.(in Chinese)杨蕊旭，胡春秀，宓余强，等．非酒精性脂肪性肝病患者血清脂质组学研究[J]．中华肝脏病杂志，2017,25(2):122-127.

[29] FENG S,GAN L,YANG CS,et al. Effects of stigmasterol andβ-sitosterol on nonalcoholic fatty liver disease in a mouse model:A lipidomic analysis[J]. J Agric Food Chem,2018,66(13):3417-3425.

[30] PREUSS C,JELENIK T,BDIS K,et al. A new targeted lipidomics approach reveals lipid droplets in liver,muscle and heart as a repository for diacylglycerol and ceramide species in non-alcoholic fatty liver[J]. Cells,2019,8(3):277.

[31] WANG J,MA Q,LI Y,et al. Research progress on traditional Chinese medicine syndromes of diabetes mellius[J]. Biomed Pharmacother,2020,121:109565.

[32] GU LM,CAO PR,GU C. Correlation between traditional Chinese medicine syndrome and clinical biochmical indexes of non-alcoholic fatty liver[J]. J Nanjing Univ Tradit Chin Med,2019,35(6):738-740.(in Chinese)顾立梅，曹培让，顾超．非酒精性脂肪肝中医证型及临床生化指标相关性研究[J]．南京中医药大学学报，2019,35(6):738-740.

[33] LI ZG,JIANG HX,JIAO YT. Literary analysis on distribution of traditional Chinese medicine syndromes of non-alcoholic fatty liver disease[J]. Chin J Tradit Chin Med Pharm,2017,32(10):4713-4715.(in Chinese)李志国，姜韩雪，焦云涛．非酒精性脂肪性肝病中医证型分布的文献分析[J]．中华中医药杂志，2017,32(10):4713-4715.

[34] MA X,GU HT,ZHAO Y. Serum metabolomics study on nonalcoholic fatty liver disease with liver damage of different syndromes[J]. Chin J Tradit Chin Med Pharm,2017,32(3):1246-1250.(in Chinese)马欣，顾宏图，赵瑜．不同证候的非酒精性脂肪肝合并肝损伤患者的血清代谢组学分析[J]．中华中医药杂志，2017,32(3):1246-1250.

[35] DAI J,SUN S,CAO J,et al. Similar connotation in chronic hepatitis B and nonalcoholic fatty liver patients with dampness-heat syndrome[J]. Evid Based Complement Alternat Med,2013,2013:793820.

[36] GUAN W,LI RY,GUO JL. Analysis of mechanism of Xiaoyaowan on rats with nonalcoholic fatty liver disease and syndrome of liver depression and spleen deficiency by1H-NMR metabolomic[J].Chin J Exp Tradit Med Form,2019,24(19):99-111.(in Chinese)关伟，李若瑜，郭继龙．基于1H-NMR代谢组学技术分析逍遥丸干预非酒精性脂肪肝肝郁脾虚证大鼠的作用机制[J]．中国实验方剂学杂志，2019,24(19):99-111.

[37] LI RY,MIAO YC,LI ML. Urinary metabolomic study on liver depression and spleen deficiency syndrome of nonalcoholic fatty liver in rats[J]. Chin J Basic Med Tradit Chin Med,2019,24(19):99-111.(in Chinese)李若瑜，庙宇船，李明磊．大鼠非酒精性脂肪肝肝郁脾虚证的尿液代谢组学研究[J]．中国中医基础医学杂志，2019,24(19):99-111.

Relative Articles

[1]	Longchuan ZHU, Wei WU, Dakai GAN, Wei ZHANG, Yizhen XU, Molong XIONG. Clinical application value of a predictive model for the efficacy of third-generation cephalosporin in treatment of community-acquired spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2024, 40(2): 306-311. doi: 10.12449/JCH240214
[2]	Junyuan ZHU, Yifu XIA, Yanmei DU, Chunqing ZHANG. Efficacy of percutaneous transhepatic variceal embolization alone or in combination with partial splenic embolization in treatment of portal hypertensive hemorrhage in liver cirrhosis： A Meta-analysis[J]. Journal of Clinical Hepatology, 2024, 40(1): 89-95. doi: 10.12449/JCH240116
[3]	Xinxin RONG, Yuanyuan XU, Guangde YANG, Xia WANG, Juanjuan FU, Li LI, Xiucheng PAN. Efficacy and safety of tenofovir alafenamide fumarate in patients with first-time hepatitis B virus-related decompensated cirrhosis[J]. Journal of Clinical Hepatology, 2024, 40(10): 2008-2013. doi: 10.12449/JCH241013
[4]	Zhisong NI, Junhan WEN, Weiwei ZHAO, Shoujun YU, Liang HAO, Yu CHENG, Xin LIU. Neoadjuvant therapy for hepatocellular carcinoma： Current situation and prospects[J]. Journal of Clinical Hepatology, 2023, 39(11): 2697-2704. doi: 10.3969/j.issn.1001-5256.2023.11.027
[5]	Xiaopeng DING, Jun TIE, Jiahao YU, Pengwei REN, Guoyun XUAN, Shuoyi MA, Changcun GUO, Ying HAN, Xinmin ZHOU. Efficacy and safety of programmed death-1 inhibitor combined with transarterial chemoembolization and anti-angiogenic drugs in treatment of advanced hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1086-1091. doi: 10.3969/j.issn.1001-5256.2022.05.021
[6]	Hongtu GU, Honglian GUI, Lieming XU, Qing GUO, Qing XIE, Changqing ZHAO. Clinical effect of Fuzheng Huayu tablets combined with entecavir in the treatment of chronic hepatitis B liver fibrosis[J]. Journal of Clinical Hepatology, 2021, 37(2): 309-313. doi: 10.3969/j.issn.1001-5256.2021.02.013
[7]	Qianmei CAO, Zhechuan MEI. Predictive factors for the therapeutic effect of terlipressin combined with albumin in hepatorenal syndrome[J]. Journal of Clinical Hepatology, 2021, 37(10): 2439-2443. doi: 10.3969/j.issn.1001-5256.2021.10.038
[8]	Meng PeiPei, Liu Yao, Zhou MeiYue, Yu Hao, Yang YuYing, Jiang YuYong. Effect of anti-liver fibrosis Chinese patent drugs in preventing renal hypofunction associated with alcoholic liver disease[J]. Journal of Clinical Hepatology, 2020, 36(9): 2030-2034. doi: 10.3969/j.issn.1001-5256.2020.09.024
[9]	Gao BinCheng, Guo Hui, Sun Le, Zhou Jie, Jiang DongMei. Clinical effect of two targeted drugs in treatment of advanced hepatocellular carcinoma: A comparative analysis[J]. Journal of Clinical Hepatology, 2018, 34(8): 1689-1692. doi: 10.3969/j.issn.1001-5256.2018.08.19
[10]	Zhao JingFeng, Liu Qun, Wang XiuYan, Zhang Yang, Liang LiWei, Gan Yu. Efficacy of Yunnan white medicinal powder combined with somatostatin and pantoprazole in treatment of liver cirrhosis complicated by upper gastrointestinal bleeding and its effect on inflammatory factors[J]. Journal of Clinical Hepatology, 2018, 34(1): 92-96. doi: 10.3969/j.issn.1001-5256.2018.01.019
[11]	Cui MeiLan, Jia YanSheng, Yan HuiMin, Kang HaiYan, Wang Yan, Yin ShuYing, Zheng HuanWei. Clinical effect of endoscopic dense ligation in treatment of esophageal variceal bleeding[J]. Journal of Clinical Hepatology, 2018, 34(8): 1683-1688. doi: 10.3969/j.issn.1001-5256.2018.08.018
[12]	Ge HongYan, Li PeiXia, Zhang YangYang, Wang LiLi, Wei YaoLing. Clinical effect of octreotide combined with an increased amount of fluid infusion in treatment of intractable cirrhotic ascites[J]. Journal of Clinical Hepatology, 2018, 34(1): 97-100. doi: 10.3969/j.issn.1001-5256.2018.01.020
[13]	Cui MeiLan, Jia YanSheng, Kang HaiYan, Yin ShuYing, Zheng HuanWei. Efficacy of endoscopic sclerotherapy with lauromacrogol in treatment of severe esophageal variceal bleeding[J]. Journal of Clinical Hepatology, 2017, 33(12): 2321-2325. doi: 10.3969/j.issn.1001-5256.2017.12.013
[14]	Zhang DongXu, Luo ZiYi. Clinical effect of esophageal variceal ligation in treatment of esophageal variceal bleeding in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2017, 33(1): 76-81. doi: 10.3969/j.issn.1001-5256.2017.01.016
[15]	Ren CaiYuan, Ren Feng, Li JunFeng, Ding Mei, Chen Yu, Duan ZhongPing, Zhang HuanHu. Clinical effect of Pien Tze Huang in treatment of guinea pigs with cholecystitis induced by lithocholic acid given by gavage[J]. Journal of Clinical Hepatology, 2017, 33(5): 905-908. doi: 10.3969/j.issn.1001-5256.2017.05.023
[16]	Liang XieEr, Chen YongPeng. Role of liver fibrosis assessment in decision-making and efficacy surveillance for antiviral therapy in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2016, 32(11): 2058-2061. doi: 10.3969/j.issn.1001-5256.2016.11.008
[17]	Liu TieJun. Therapeutic effect and advantages of percutaneous transhepatic variceal embolization in treatment of variceal rupture and bleeding after devascularization: an analysis of 34 cases[J]. Journal of Clinical Hepatology, 2015, 31(11): 1867-1869. doi: 10.3969/j.issn.1001-5256.2015.11.023
[18]	Huang LingYing, Zhou ZhenHua, Sun XueHua, Li Man, Zhu XiaoJun, Jin ShuGen, Zhang Xin, Gao YueQiu. Clinical efficacy of Biejiaruangan compound tablets in treatment of primary biliary cirrhosis[J]. Journal of Clinical Hepatology, 2015, 31(2): 181-184. doi: 10.3969/j.issn.1001-5256.2015.02.009
[19]	Du Ying, Fang Lei. Clinical efficacy of traditional Chinese medicine/herbal decoction combined with ursodeoxycholic acid for primary biliary cirrhosis:a meta-analysis[J]. Journal of Clinical Hepatology, 2015, 31(1): 68-73. doi: 10.3969/j.issn.1001-5256.2015.01.015
[20]	Wu JiYuan, Zhang DongQin, Zhang HaiYue, Wang LuWen, Gong ZuoJiong. Efficacy and safety of transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with cirrhosis: a meta-analysis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1272-1278. doi: 10.3969/j.issn.1001-5256.2014.12.010

Supplements(0)

Cited By

Cited by

Periodical cited type(12)

1.	赵迪，徐佳. 中医药抗肝纤维化疗效评价的探索. 西部中医药. 2023(04): 150-153 .
2.	张涛，王之通，吴眉，张斌，朱晓骏，李运东. 消胀方联合恩替卡韦治疗乙肝肝纤维化/肝硬化疗效观察. 现代中西医结合杂志. 2023(06): 759-764 .
3.	程丹颖，郭朋，孙凤霞，王晓静，李炜，陈琴，周桂琴，王融冰，邢卉春. 恩替卡韦联合鳖甲煎丸治疗慢性乙型肝炎肝纤维化瘀血内阻证的临床疗效及其对中医证候积分的影响. 中华肝脏病杂志. 2023(06): 608-613 .
4.	范灵芝，郭峰，赵年欣. 和血柔肝方治疗慢性乙型肝炎肝纤维化肝郁脾虚证的临床研究. 云南中医中药杂志. 2021(01): 54-57 .
5.	王慧，靳菲菲，李锦秀. 恩替卡韦联合扶正化瘀片治疗慢性乙型肝炎后肝硬化的临床效果分析. 内科. 2021(04): 455-458 .
6.	韦冬珏，张凤英，周莹，王振常. 中医药联合干细胞抗肝纤维化的思路与进展. 中华中医药学刊. 2019(01): 76-81 .
7.	冯宇，刘雪梅，罗伟生，陈林，李志峰，梁健钦，张国松，奉建芳. 大孔树脂纯化荔枝核总黄酮工艺研究. 中草药. 2019(09): 2087-2093 .
8.	郑琼娜，武俏俏，马哲乐，张贤菲，干方敏，孔庆名. 低分子肝素钠对小鼠实验性肝纤维化干预作用的初步研究. 中国临床药理学与治疗学. 2019(05): 511-516 .
9.	杨晓. 中医药防治肝纤维化用药规律探讨. 内蒙古中医药. 2019(05): 135-136 .
10.	延国威，王晓忠，范灵芝，郭峰，王燕. 和血柔肝方治疗慢性乙型肝炎肝纤维化临床研究. 中国中医药信息杂志. 2019(08): 24-29 .
11.	孙凤霞，王琮，孙宁宁，徐春军. 以慢性乙型肝炎为例谈中医专业学生实习带教. 继续医学教育. 2018(03): 81-83 .
12.	陈艳，杨永平. 中医药阻断逆转肝纤维化的现状、希望与挑战. 临床肝胆病杂志. 2018(04): 689-693 . 本站查看

Other cited types(7)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views (1037) PDF downloads(184)

Metabonomics and traditional Chinese medicine syndrome of nonalcoholic fatty liver disease

DOI: 10.3969/j.issn.1001-5256.2020.08.044